According to the FDA, without loss of at least 5% of body weight Belviq, In the test, 47% of patients with type 2 diabetes. In contrast, 23% of placebo-treated patients had lost at least 5% of their weight. In type 2 diabetes, the patient Belviq 38% to 16% compared to placebo, and lost at least 5% of body weight.
After the ratification of the U.S. Food and zi xiu tang bee pollen Drug Administration (FDA) to reduce the risk of stroke and heart attack, Belviq maker said assess long-term Arena Pharmaceuticals, Post-marketing surveillance of six, including a cardiovascular test, you needs.
The Belviq non-diabetic patients with the most common side effects according to the FDA, there are headaches, dizziness and fatigue. In diabetic patients, side effects, low blood sugar and pain, and the like.
In addition, according to the company's revenue Eisai Inc., of pharmaceutical products, Belviq people take some reported problems with the heart valves and other drugs like these.
According to the website of medicine, "If the zixiutang pollen capsule deaths from stroke and risk of stroke and heart problems your, heart problems, I do not know Belviq".
Be U.S. Food and Drug Administration (FDA) approved Belviq, a new drug, its purpose in a position to fight obesity and to help people to reduce about 5% of their weight. Contraception will come to market next week.